Fermenta Biotech Q1 Consolidated Net Profit Declines 55% YoY To ₹9.74 Cr; Revenue At ₹121.82 Cr

Market snapshot: Fermenta Biotech reported a weak consolidated financial performance for Q1 FY27, with net profit falling 55.38% YoY to ₹9.74 crore and revenue from operations declining 10.60% YoY to ₹121.82 crore. The contraction was heavily influenced by price corrections in the animal nutrition segment and the high base of the prior year, which had been supported by exceptional items.

Data Snapshot

• Consolidated net profit for the quarter ended June 30, 2026, declined to ₹9.74 crore from ₹21.83 crore in the corresponding quarter of the previous year.
• Consolidated revenue from operations for Q1 FY27 fell to ₹121.82 crore compared to ₹136.26 crore in Q1 FY26.
• Standalone net profit for the June 2026 quarter decreased by 7.7% YoY to ₹14.99 crore from ₹16.23 crore in the June 2025 quarter.

What's Changed

• Consolidated net profit declined by 55.38% YoY (derived: ₹9.74 cr vs ₹21.83 cr) due to sharp pricing contraction in animal nutrition.
• Consolidated revenue contracted by 10.60% YoY (derived: ₹121.82 cr vs ₹136.26 cr) reflecting pricing pressures in global Vitamin D3 markets.
• Standalone net profit declined 7.7% YoY (derived: ₹14.99 cr vs ₹16.23 cr), displaying better operational holding than the consolidated entity.

Key Takeaways

• Vitamin D3 animal nutrition realizations plummeted by 40% YoY, severely denting consolidated margins.
• The bottom line comparison was impacted by a high base in Q1 FY26, which featured a ₹2.7 crore non-recurring insurance gain.
• Human nutrition volumes showed a positive counter-trend, growing 18% quarter-on-quarter.
• India's revenue contribution rose to 47%, signaling a strategic shift toward domestic market stabilization.

SAHI Perspective

Fermenta Biotech is weathering a tough cyclical downturn in Vitamin D3 ingredient pricing, particularly in animal feed segments. While the consolidated numbers look weak on a YoY basis, the underlying volume growth in human nutrition (up 18% QoQ) and the rising share of domestic revenues are encouraging signs of structural stability. The key to future recovery lies in commercializing high-margin innovations like VITADEE Green®.

Market Implications

The near-term outlook for the stock remains muted as margin pressure from the animal nutrition segment is likely to persist for another quarter. However, the company's shift towards domestic markets and plant-based Vitamin D3 could act as a buffer against volatile European pricing.

Trading Signals

Market Bias: Bearish

A near-term bearish outlook is driven by the 55.38% drop in consolidated net profit to ₹9.74 crore and a 10.60% decline in revenue. Margin pressure from a 40% decline in Animal Nutrition realizations is expected to weigh on the stock until global prices stabilize.

Overweight: Nutraceuticals, Domestic APIs

Underweight: Animal Feed Ingredients

Trigger Factors:

• Recovery in global Vitamin D3 pricing, especially in European and animal feed markets.
• Market adoption and commercial revenue contribution from the newly approved VITADEE Green® product.
• Sustainable margin improvement in standalone operations.

Time Horizon: Near-term (0-3 months)

Industry Context

The global Vitamin D3 and API industry is dealing with severe oversupply and pricing corrections, especially in feed-grade segments. Companies are shifting focus toward high-margin human nutrition and vegetarian alternatives to combat margin erosion in bulk chemicals.

Key Risks to Watch

• Further decline in global Vitamin D3 realizations.
• High volatility in international export demand, particularly from Europe.
• Inability to pass on raw material cost changes amid intense competitive pricing.

Recent Developments

In July 2026, Fermenta Biotech received FSSAI approval for its plant-source Vitamin D3, VITADEE Green®, opening significant opportunities in the domestic food fortification and health supplement sectors. Additionally, the company's equity shares were listed on the National Stock Exchange of India (NSE) on July 24, 2026, which is expected to enhance liquidity and investor access.

Closing Insight

While the Q1 FY27 earnings highlight cyclical challenges, Fermenta Biotech's long-term pivot toward specialized plant-based nutrition and its successful listing on the NSE position it well for the next recovery phase.

High Performance Trading with SAHI.